Rabbit Recombinant Monoclonal CBL phospho Y674 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
IP | WB | IHC-P | Flow Cyt (Intra) | |
---|---|---|---|---|
Human | Not recommended | Tested | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/20 | Notes ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody. |
Select an associated product type
E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, PubMed:14661060, PubMed:14739300, PubMed:17094949, PubMed:17509076, PubMed:17974561). Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signaling (PubMed:15190072, PubMed:18374639, PubMed:21596750). Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation (PubMed:11896602). Ubiquitinates EGFR and SPRY2 (PubMed:17094949, PubMed:17974561). Ubiquitinates NECTIN1 following association between NECTIN1 and herpes simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1 removal from cell surface (PubMed:28381567). Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis (PubMed:15190072, PubMed:18374639). Essential for osteoclastic bone resorption (PubMed:14739300). The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:14739300). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity).
CBL2, RNF55, CBL, E3 ubiquitin-protein ligase CBL, Casitas B-lineage lymphoma proto-oncogene, Proto-oncogene c-Cbl, RING finger protein 55, RING-type E3 ubiquitin transferase CBL, Signal transduction protein CBL
Rabbit Recombinant Monoclonal CBL phospho Y674 antibody. Suitable for WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 2 publications.
pH: 7.2 - 7.4
Preservative: 0.05% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 0.1% BSA
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The CBL protein also known as C-cbl or Casitas B-lineage lymphoma proto-oncogene serves as an E3 ubiquitin-protein ligase. This protein with a molecular mass of approximately 120-130 kDa plays a critical role in the regulation of receptor tyrosine kinases. It facilitates the polyubiquitination of activated receptor proteins targeting them for degradation in the proteasome. CBL is predominantly expressed in various tissues including the hematopoietic system. It is a significant component in the control of cell signaling and helps maintain cellular homeostasis.
The CBL protein acts as a negative regulator for several signaling pathways. It integrates into signaling complexes and modulates the activation of pathways by interacting with other proteins. CBL does not act alone; it commonly forms complexes with proteins such as Grb2 and p85 influencing downstream signaling influence in pathways. This regulation prevents excessive activation of signals that can lead to cellular proliferation or differentiation abnormally.
CBL integrates into the ubiquitin-proteasome system and the Ras signaling pathway. Within these pathways CBL works to modulate cell surface receptors ensuring that signaling threshold is not surpassed. The importance of CBL in the Ras signaling pathway is highlighted by its interactions with proteins like Ras-GAP and SHP2. Through these interactions CBL controls the rate of signal transduction affecting cellular responses such as growth survival and motility.
CBL involvement has been linked to several forms of cancer and immune deficiencies. Mutations or dysregulation of the CBL gene can lead to myelodysplastic syndromes and acute myeloid leukemia. In these conditions the interaction between CBL and other proteins such as JAK2 becomes dysregulated driving abnormal cell growth and survival. Furthermore CBL’s failure to properly degrade tyrosine kinase receptors can contribute to enhanced signaling fostering oncogenic processes.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-CBL (phospho Y674) antibody [EPR2227] (ab76536) at 1/1000 dilution
Lane 1: Jurkat cell lysate at 10 µg
Lane 2: Jurkat cell lysate treated with pervanadate at 10 µg
All lanes: HRP labelled goat anti-rabbit at 1/1000 dilution
Predicted band size: 100 kDa
Observed band size: 120 kDa
Intracellular flow cytometric analysis of permeabilized Jurkat cells, un-treated (green) or pervanadate treated (red) using ab76536 at a 1/20 dilution, and pervanadate-treated Jurkat cells using the same antibody pre-incubated with phospho-CBL peptide (blue) or non-phospho-CBL peptide (orange).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com